Ecolab Inc. vs Incyte Corporation — how do they compare? Ecolab Inc. trades at $286.29 (market cap $79.79B), while Incyte Corporation trades at $120.45 (market cap $24.54B). The key difference: Ecolab Inc. is far larger — about 3.3× Incyte Corporation's market cap, and Ecolab Inc. pays a 1.03% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| ECL | INCY | |
|---|---|---|
Market Cap | $79.79B | $24.54B |
Sector | Consumer Cyclical | Health |
52-Week High | $308.35 | $129.93 |
52-Week Low | $245.73 | $81.61 |
Enterprise Value | $88.57B | $20.04B |
Dividend Yield | 1.03% | — |
Trailing returns across standard periods
Ecolab produces and markets cleaning and sanitation products for the hospitality, healthcare, and industrial markets. The firm is the global market share leader in this category with a wide array of products and services, including dish and laundry washing systems, pest control, and infection control products. The company has a strong hold on the U.S. market and is looking to increase its profitability abroad. Additionally, Ecolab serves customers in water, manufacturing, and life sciences end markets, selling customized solutions.
Read more on ECL →Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →